//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
Medical Oncologist | Thoracic & Melanoma Immuno-Oncology | Translational & Real-World Evidence TIL biology and cross-tumour IO research CCIT-DK, Copenhagen
Yago Garitaonaindia MD
Also worth considering: are we even measuring the right mechanism? Some mAbs may derive clinical activity from Fc-mediated effects (as seen with CTLA-4), not just target blockade. Nice perspective here: ascopubs.org/doi/10.1200/...
Honoured to join @JNCI_NOW as Social Media Editor 🚀 Excited to contribute to the digital voice of JNCI Journals and help amplify clinically relevant research with global impact. Scientific publishing is evolving and context & community matter more than ever #Oncology #SciComm
We’ve been discussing this paper for weeks. Now the phase 3 trial in @natureportfolio.nature.com carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩 🔎 Social media amplification requires critical judgment
New here on Bluesky 🚀 Medical oncologist focused on clinical research, IO and translational science #Oncology #TranslationalResearch #Cancer
4mo
4mo
3mo
Does TIGIT benefit no one… Or does it benefit a biologically defined subset we failed to identify? 🤔 All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts. Is it time for true precision IO? 🔬 #ImmunoOncology #PrecisionMedicine #Biomarkers
4mo
3mo